Weight plateau was defined as a weight change <5% over a 12-week interval and all subsequent 12-week intervals...
Across the four BMI categories of overweight, class I, class II, and class III obesity, the median time to weight plateau was 24.3, 26.0, 36.1, and 36.1 weeks, respectively.
Multivariate analysis showed that higher doses of tirzepatide (10 and 15 mg), younger age, and female sex were associated with a longer time to weight plateau, while BMI and waist circumference had no association...
Another reason to highlight the weight plateau is that it can contribute to negative clinical experience as it is often mistakenly interpreted as the end of the intervention's benefit or even as loss of treatment effect. Importantly, the SURMOUNT-4 study demonstrated that compared to withdrawal of tirzepatide, continued treatment with tirzepatide after initial weight reduction promoted maintenance of this initial weight reduction as well as additional weight reduction. Similar findings have been reported for other obesity management medications and for lifestyle interventions.
Informing clinicians and patients to expectations over the course of treatment can improve patient experience. In the current study, the weight loss at the time of weight plateau was slightly lower than end-of-study weight reduction; as such the degree of weight reduction at the weight plateau could be used to predict longer-term weight reduction from treatment and support decisions to modify treatment if necessary.
glp1effect.com
